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Abstract
Background: Depression is a common condition that typically has a relapsing course. Effective interventions
targeting relapse have the potential to dramatically reduce the point prevalence of the condition. Mindfulness-
based cognitive therapy (MBCT) is a group-based intervention that has shown efficacy in reducing depressive
relapse. While trials of MBCT to date have met the core requirements of phase 1 translational research, there is a
need now to move to phase 2 translational research - the application of MBCT within real-world settings with a
view to informing policy and clinical practice. The aim of this trial is to examine the clinical impact and health
economics of MBCT under real-world conditions and where efforts have been made to assess for and prevent
resentful demoralization among the control group. Secondary aims of the project involve extending the phase 1
agenda to an examination of the effects of co-morbidity and mechanisms of action.
Methods/Design: This study is designed as a prospective, multi-site, single-blind, randomised controlled trial using
a group comparison design between involving the intervention, MBCT, and a self-monitoring comparison
condition, Depression Relapse Active Monitoring (DRAM). Follow-up is over 2 years. The design of the study
indicates recruitment from primary and secondary care of 204 participants who have a history of 3 or more
episodes of Major Depression but who are currently well. Measures assessing depressive relapse/recurrence, time to
first clinical intervention, treatment expectancy and a range of secondary outcomes and process variables are
included. A health economics evaluation will be undertaken to assess the incremental cost of MBCT.
Discussion: The results of this trial, including an examination of clinical, functional and health economic outcomes,
will be used to assess the role that this treatment approach may have in recommendations for treatment of
depression in Australia and elsewhere. If the findings are positive, we expect that this research will consolidate the
evidence base to guide the decision to fund MBCT and to seek to promote its availability to those who have
experienced at least 3 episodes of depression.Trial Registration
Australian New Zealand Clinical Trials Registry: ACTRN12607000166471
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The 1 year prevalence of major depressive disorder
(MDD) in Australia has consistently been measured
above 4% [1,2] and it is commonly a recurrent condi-
tion. At least 60% of people who have had one major
depressive episode will have another, mostly within 2
years of the index episode [3]. Seventy percent of those
who have had two episodes will have a third, and 90%
of those with three episodes will have a fourth [4]. Effec-
tive interventions targeting relapse, particularly in peo-
ple with a history of three or more episodes of
depression, could dramatically reduce the point preva-
lence of the condition [5]. Mindfulness-based cognitive
therapy (MBCT) is a group-based program that inte-
grates aspects of cognitive behaviour therapy (CBT)
with components of a Mindfulness-Based Stress Reduc-
tion program [MBSR - [6]]). It was developed specifi-
cally with the aim of reducing recurrence rates of MDD
by increasing patients’ ability to recognize and disengage
from depression-related ruminative thought patterns
through the cultivation of mindfulness. A recent meta-
analysis [7] confirmed a highly significant reduction in
relapse for MBCT compared to treatment as usual
(TAU) for people with three or more episodes of
depression, with effects at least equal to maintenance
antidepressant medication. MBCT is now included in
the United Kingdom’s National Institute of Health and
Clinical Excellence (NICE) Guidelines for prevention of
depressive recurrence for patients who have experienced
three or more episodes of depression [8].
T h ew o r kr e v i e w e db yC h i e s ae ta l[ 7 ]c o u l db es e e n
as meeting the core requirements of phase 1 transla-
tional research in which the safety and efficacy of treat-
ments for selected volunteers are tested in randomised
controlled trials (RCTs) [9]. Although mentioned in the
NICE guidelines, MBCT has not been similarly recom-
mended in other countries and its implementation
within clinical services is typically not routine. There is
a need now to move to phase 2 translational research -
the application of MBCT within real-world settings with
a view to directly informing policy and clinical practice
[9,10]. There are a number of important priorities to
consider within a phase 2 agenda for MBCT.
Advancing the translational research agenda related to
MBCT
Transportability and effectiveness
MBCT trials to date could be argued as being efficacy
studies in which the developers of MBCT either pro-
vided the therapy [11,12], or provided direct training
[13-15] or direct consultation [16] to the therapists.
Hence, a priority for phase 2 translational research is to
address the transportability of the program [17] - that
is, to what extent can MBCT be successfully adapted
and applied in settings away from the original develo-
pers. In addition to the general question of replication
of MBCT findings, it is unclear what level of training is
required to become an effective MBCT facilitator. For
instance the Centre for Mindfulness Research and Prac-
tice in the School of Psychology, Bangor University
offers a Masters course with prerequisites including at
least 6-12 months with a personal mindfulness practice
a n dc o m p l e t i o no fa n8 - w e e km i n d f u l n e s sc o u r s e .
Undoubtedly this makes for a comprehensive and thor-
ough training but the cost and demands on therapists is
high when considered against typical training require-
ments for other brief therapeutic models in regular use
(e.g., see http://iptinstitute.com/). The demonstration of
positive effects achieved by instructors trained in a
briefer and more readily generalisable model could be
valuable in establishing the case for transportability of
the delivery of MBCT.
Antidepressant medication
In considering the general application of MBCT more
needs to be known about combination treatment with
MBCT and antidepressants [18]. Trials of MBCT to
date have typically been structured so as to consider
MBCT as an alternative to maintenance anti-depressant
medication (m-ADM) rather than a complement. This
stands in some practical tension with clinical guidelines
for treatment of people with 3 or more prior episodes,
which generally advise m-ADM for up to 3 years [19].
Only one study to date has examined outcomes for
MBCT where participants continue their usual treat-
ment, including m-ADM [16]. At baseline, the majority
of participants were taking antidepressant medication
with the rate of antidepressant use non-significantly
higher in the MBCT group (73%) compared TAU (61%).
Of interest, the MBCT relapse rate in this trial was one
of the lowest recorded compared to other MBCT groups
where anti-depressants was disallowed. Over the course
of the follow-up period, the rate of antidepressant use
d e c r e a s e di nt h eM B C Tg r o u pb u tn o ti nt h eT A U
group, however, regression to the mean may account for
this finding as there were no group differences in the
rate of antidepressant medication use at any time point.
More detailed research examining the combined role of
MBCT and antidepressants is required. Difficulties in
interpreting the findings from this study could be seen
as an argument for stratification according to m-ADM
in a pragmatic study.
Longer follow up
To date, the follow-up period in RCTs of MBCT has
been limited to around 12 months excepting one 18
month follow-up study [15]. One observational study
suggests improvements in depression scores following
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role in relapse prevention has not yet been more rigor-
ously examined over this longer time frame. The vulner-
ability occasioned by having three or more prior
episodes persists over many years [21] so MBCT use-
fully could be studied for potential protective effect over
longer time spans. MBCT involves substantial personal
commitment for participants including perhaps signifi-
cant lifestyle changes in the longer term, so for this rea-
son also, information on enduring benefits is very
relevant.
Health Economics
Kuyken et al [14] examined the cost effectiveness of
MBCT compared to m-ADM. Although not conclusive,
this work suggested that MBCT was more expensive
than m-ADM over the first 12 months with costs then
converging and MBCT becoming cheaper over the sub-
sequent 3 months. The authors speculated that the cost-
effectiveness of MBCT may increase over time and
recommended examining the cost-effectiveness of
MBCT over longer follow-up periods. More generally,
later phase translational research questions would be
served by a health economics study and analysis taking
into account local service context, real-world conditions
including combined treatment with anti-depressant
medication and multiple economic perspectives.
Continuing phase 1 agenda
Mechanisms of action Although a number mediation
analyses have been published in relation to MBCT, the
mechanisms of action remain unclear. Mediation studies
often have been small and hence with low power, or
limited by being observational in nature [13,20,22-24].
So to consider some possible mediation factors needing
further examination:
￿ Time spent practicing mindfulness meditation cor-
relates with reductions in mood disturbance and
relapse but how much practice is required for thera-
peutic benefit in MBCT remains unsettled
[13,20,25].
￿ Evidence for the role of mindfulness scores in
mediating depressive relapse outcomes in MBCT is
inconsistent [23,26].
￿ There has been some support for proposed interre-
lationships between mindfulness, rumination and
depression in an observational study [20] and from a
small RCT [24] but the findings await replication in
a larger controlled design.
To date the evidence supporting a central mediation
role for mindfulness and rumination mediating out-
comes in terms of depression and especially depressive
relapse is, at best, patchy.
Comorbidity Anxiety disorders are frequently associated
with depression and, importantly, are a significant risk
factor for the development of depression [27]. Relaxa-
tion, although not a primary goal of the mindfulness
practices taught in MBCT, is commonly experienced
through many of the exercises [28] and learning of
relaxation skills may assist participants with anxiety dis-
orders. Moreover, the process of rumination may be
similar in anxiety and depression, although the content
may differ [29]. A meta-analysis of previous studies sug-
gests that mindfulness-based interventions may have a
positive impact on anxiety [30]. However, the mediation
role of anxiety in long-term management of depression
with MBCT has not yet been examined.
Need to prevent and assess for resentful demoralisa-
tion “Resentful demoralisation” is a well-recognised bias
that may arise in control group participants whereby the
belief that they are not receiving a desirable treatment
negatively affects their attitude and behaviour, and as a
consequence, the outcome results. Thus, a criticism that
that has been leveled at much of the work so far with
MBCT is that the promising findings in favour of
MBCT may be a reflection of relative deterioration in
the TAU group rather than improvement in the MBCT
group [31]. As noted by Everitt and Wessely [32], parti-
cipants entering a trial “are likely to believe that the
new therapy is about to solve all their problems. Why
else would it be featuring in the trial?” (p. 16). If a parti-
cipant is then not provided with this promising new
therapy, he or she may feel disappointed and have nega-
tive expectations of their ongoing involvement. If such
negative expectations are present, the seemingly positive
results for the experimental treatment may in fact be
accounted for by the negative effects in the control. The
control condition in this scenario possibly acquires
properties of a nocebo [33]. Given that trial participants
in MBCT studies are typically highly vulnerable to
depression and therefore negative thinking, this effect
could be important to consider in study design.
Aims of trial
Within the parameters of phase 2 translational research,
the aim of this effectiveness study is to examine the
clinical impact and health economics of MBCT where
efforts are made to assess for and prevent resentful
demoralization and under real-world conditions - within
a population representative of the intended target audi-
ence, that is, people with a history of depression regard-
less of their antidepressant regimen. For a long-term
preventive intervention evidence of a longer duration of
effect would be more desirable than the 12-18 month
periods so far examined and 2-year follow-up is planned
in this study. The portability of MBCT training has not
been assessed and this project will investigate outcomes
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may not have a long-standing and deep knowledge of
the intervention provided.
The secondary aim of the project is to provide for a
detailed examination of the mechanisms by which this
form of therapy may prevent depressive relapse, with this
examination structured in a way so as also to progress
the understanding of the clinical applicability of MBCT
as a treatment for relapse prevention in depression.
MBCT may act to reduce relapse through a number of
mechanisms outlined in the model shown in Figure 1.
According to this model, the two primary mediators for
outcome in terms of reduced depressive relapse are 1)
increased mindfulness and 2) improved relaxation skills
which occur as the result of adopting a meditation prac-
tice. We have postulated that these factors may have
positive downstream effects on other secondary mediat-
ing factors such as rumination, neuroticism, medication
adherence and anxiety. Although it will not be practic-
able to explore validation of this causal nexus fully, we
will use it to guide our choice of measures through the
research plan that follows.
Methods/Design
Research design
This study is a prospective, multi-site, single (rater)-
blind, RCT using a group comparison design between
involving the intervention, MBCT, and a comparison
condition, Depression Relapse Active Monitoring
(DRAM) with follow-up over 2 years. Both interventions
are provided in addition to TAU. All participants receive
DRAM with half the sample randomised to additionally
receive MBCT. Participants continue their usual treat-
ment during the course of their participation in the
trial. We avoid any attempts to standardise routine clini-
cal care including medication beyond the recommenda-
tions of DRAM. The study is being conducted in
compliance with the Helsinki Declaration and has been
approved by the following governing ethics committees:
Alfred Hospital Ethics Committee (280/07); Barwon
Health Research and Ethics Advisory Committee (07/
86); Monash University Standing Committee on Ethics
in Research Involving Humans (CF07/1275-2007/
019MCC; CF08/1031-2008000509); Peninsula Health
Human Research & Ethics Committee (2007-53); South-
ern Health Human Research Ethics Committee
(07056B); and The Melbourne Clinic Research Ethics
Committee (189). Written informed consent is required
for all participants.
The Interventions
MBCT
Description MBCT is a manualised program delivered
by an instructor in 8 weekly 2-hour group training ses-
sions involving up to 10 clients; optional 3-monthly
‘booster sessions’ are also delivered. Sessions incorporate
mindfulness practices including meditation and also
CBT exercises [28]. Homework for participants includes
formal daily meditation practices and exercises for the
development of mindful awareness within everyday
activity.
Therapist training MBCT instructors are selected from
a locally-developed MBCT professional training program
headed by GM, who was trained by one of the develo-
pers of MBCT (ZS). The training program is, we believe,
uniquely geared toward efficiently training experienced
mental-health clinicians who do not necessarily have
any background or knowledge of meditation to be
MBCT instructors. Thus, positive results from this trial
favouring MBCT would suggest that it can be effectively
provided by instructors who may not have a long-stand-
ing and deep knowledge of the intervention and who
are trained by someone outside of the original develo-
pers of the intervention. This will add further evidence
in terms of the important issue of the transportability
and generalisability of treatment [7].
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Motivation to 
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Participation 
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Figure 1 Proposed mechanisms for MBCT.
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that is a variation of the MBCT therapy group but
adapted for the training situation, with some variation
to the exercises so as to make them more suitable for
experiential participation and learning by therapists
rather than patients with depression. Since it is not
assumed that trainees already have a meditation prac-
tice, following the 8-week course, there is a break for a
minimum period of 1 month so that participants can
consolidate their personal practice and associated learn-
ing. The program then ends with an intensive teacher
development retreat over 3 full days which continues to
emphasise personal practice as well as concentrated and
closely coached practice in leading meditations, discus-
sions and other aspects of the course (total of 44 hours
training).
Quality control MBCT sessions are video-taped with
the patients’ permission (camera visual field focused on
clinician) for the purposes of supervision and assessing
treatment fidelity. An independent audit of the therapy
will be undertaken across the therapy groups using two
sessions randomly selected from each group. Sessions
will be rated by a clinical psychologist with training and
experience in MBCT using the MBCT-Adherence Scale
[34].
Depression Relapse Active Monitoring (DRAM)
To reduce the discrepancy between groups in treatment
expectation and thus mitigate against the risk of trigger-
ing resentful demoralisation, we developed a comparison
condition called “Depression Relapse Active Monitoring”
(DRAM) as an alternative to a TAU-only control.
DRAM comprises training on the management of
depression through the monthly self-monitoring that
forms part of the research assessments. To support
DRAM, participants are provided with a manual (also
available on the project website) and a wallet-sized card
which has self-monitoring items, emergency phone
numbers and project contact and web details printed on
it. Training in DRAM is provided by research assistants
during the intake assessment interview. By being able to
fairly present the project as having a potential benefit
for all participants, we expect to not only reduce the
potential for resentful demoralization but also selection
bias. The project title, marketing name and marketing
materials have also been developed so as to reflect both
conditions in an unbiased manner.
Power analysis
A power analysis was conducted using estimates of
annual relapse rates obtained from the literature. Sys-
tematic reviews and meta analyses were mainly utilised
including: no treatment (or placebo) only [35-38]; psy-
chological treatment alone; effect in recurrent depres-
sion of medication alone [35,37,38]; and combined
psychological and pharmacotherapy [39,40]. From these
sources, anticipated relapse rates over a 2-year period
were: no treatment, 56%; MBCT alone, 31%; medication
alone, 31%; and MBCT and medication together, 15%.
Based on findings from recruitment in our pilot study,
we assumed that 70% of the sample would be taking at
least some reasonably effective dose of medication, and
30% would not. Applying the subgroup specific odds
ratios suggested the following relapse rates as likely over
a 26-month period: MBCT group 21.5%; and DRAM
group 41.7%. A power analysis showed that to detect
this difference using an uncorrected chi-squared statistic
at 80% power and a = 0.05 would require a sample size
of 82 participants to complete the full 26 months in
each of the MBCT and DRAM groups [41]. Further,
assuming a dropout rate of 20% led to a recruitment
target of 102 participants for each group.
Participants
Recruitment
Participants are recruited from private and public com-
munity health services and through notices placed in
local media in metropolitan Melbourne and the regional
city of Geelong, located in the state of Victoria, Austra-
lia. Also targeted are public mental health services
across multiple sites and ECT clinics where the more
severely affected individuals are likely to be treated as,
from a health economics perspective, this group is likely
to have the greatest impact on costs.
Selection criteria
Inclusion criteria include meeting DSM-IV criteria for
three previous episodes of MDD [DSM-IV diagnosis of
either MDD (Recurrent) or Bipolar Disorder I or II],
aged between 18-75 years, and able to speak and read
English fluently. Current use of medication, including
antidepressants and mood stabilisers, is allowed. Exclu-
sion criteria include: current episode of MDD; current
symptoms of a psychotic disorder, or a past diagnosis of
a psychotic disorder where the treating clinician believes
the therapy may be contraindicated; current significant
eating disorder or obsessive-compulsive disorder;
organic mental disorder or pervasive developmental
delay; current borderline or antisocial personality disor-
der; current alcohol or drug dependency other than
tobacco; current benzodiazepine intake of more than 20
mg diazepam equivalent; and inability to give informed
consent.
Randomisation
Assignment of individual participants to MBCT +
D R A Mo rD R A Ma l o n ei su n d e r t a k e nb yt h es t u d ys t a -
tistician using a minimization routine balancing num-
bers in groups as randomisation proceeds [42]. The
statistician works independently of staff involved in the
recruitment, assessment and management of participants
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differences in other treatment exposures, randomisation
is stratified by: medication (currently taking antidepres-
sants and/or mood stabilisers: yes/no); site of referral
(primary care, secondary care, specialist clinic): diagnosis
(bipolar disorder: yes/no); and gender.
Retention
Given the 2-year follow-up proposed for this study, and
the requirement of monthly assessments, attention to
retention strategies is crucial to the success of the trial
as completeness of follow-up has a significant effect on
the quality and validity of the analysis. Strategies we
implement to limit attrition include: minimising
response burden as far as possible such as having flex-
ibility in how assessments can be completed; employing
staff experienced in communicating with research parti-
cipants; establishing a project name ("DARE - Depres-
sion Awareness Recovery Effectiveness”) and identity
(professionally designed project logo, website, wallet
card with key contact numbers); provision of reimburse-
ment that acknowledges the participants’ time and
effort; and greeting cards and quarterly newsletters to
maintain positive contact between assessments.
Measures
Diagnosis and eligibility
Composite International Diagnostic Interview 2.1
Auto Lifetime version (CIDI-LT) Diagnostic inclusions
and exclusions are assessed using the appropriate sec-
tions of the Composite International Diagnostic Inter-
view 2.1 Auto Lifetime version (CIDI-LT). The CIDI 2.1
is a highly standardised instrument designed to be admi-
nistered by lay interviewers. The CIDI 2.1 was used in
preference to the more recent World Health Organisa-
tion CIDI (WHO CIDI) because the latter is not avail-
able in a 12-month form and the former had stronger
evidence supporting its validity [43,44]. To minimise
participant burden, in this design exclusion criteria
related to psychosis, personality disorder, organic mental
disorder or pervasive developmental delay are not for-
mally assessed. Instead, reliance is placed on the treating
clinician to screen out ineligible candidates.
Primary outcome: relapse/recurrence of MDD
Composite International Diagnostic Instrument 2.1
Auto 12 month version (CIDI-12) Episodes of depres-
sion are assessed retrospectively during a face-to-face
interview using the CIDI Auto 2.1 12 month affective
disorders modules. Several questions from the WHO
CIDI are added to give more precise details of episodes
including number of episodes (where there was at least
2 weeks in remission between episodes), the month that
the first/only depressive episode commenced, and total
number of days depressed.
Patient Health Questionnaire In the study the Patient
Health Questionnaire-2 [PHQ-2 - [45]] and the PHQ-9
[46] are used to monitor for the presence and severity
of depressive symptoms each month. The PHQ-2 is a
screening tool for depression that comprises two ques-
tions addressing anhedonia and depressed mood with
frequency ratings 0 (not at all) to 3 (nearly every day).
The PHQ-9 comprises the nine criteria upon which the
diagnosis of DSM-IV depressive disorders is based. Both
instruments have been found to be reliable and valid
[45,46]. As part of DRAM, participants are trained on
how to complete the PHQ-2 and PHQ-9 then prompted
monthly to self-monitor via their preferred medium of
SMS, telephone or internet. To facilitate monitoring, the
PHQ-2 is provided on a wallet card which also has their
project ID and password for online completion. Partici-
pants reporting scores ≥3 are directed to complete the
PHQ-9 and encouraged to seek appropriate assistance
using automated feedback. The full PHQ-9 is adminis-
tered every 3 months regardless of PHQ-2 score.
Time to first clinical intervention We expect an active
property of DRAM in prompting participants to seek
help for depressive symptoms at an earlier stage than
would occur without this self-monitoring intervention.
Thus, although providing some control for treatment
expectation and ethically optimising the design, this
intervention may reduce the between-group differences
with respect to depressive relapse so that time to first
clinical intervention is an important adjunctive measure.
The General-practice Users’ Perceived-need Inventory
(GUPI) short form [47] is a three-item measure of per-
ceived need for mental health care that was slightly
modified to assess whether there had been a clinical
intervention in the past 3 months, and if so, when this
was initiated. Study design also includes tracking of
medication changes over the course of the project with
onset of an antidepressant or increase in dose assumed
to signal an incipient relapse.
Patient expectations
Credibility/Expectancy Questionnaire The Credibility/
Expectancy Questionnaire [CEQ - [48]]) is used to
assess therapy credibility and client expectancy for
improvement, as potential confounds for outcome. The
CEQ has high internal consistency and good test-retest
reliability and has been shown to discriminate between
different treatment rationales [48]. The instructions for
t h eC E Qa r em o d i f i e ds oa st ob ea p p r o p r i a t ef o rp a r t i -
cipants in both groups.
Belief about relapse Belief about relapse is assessed by
asking participants to indicate how likely it was that
they would experience depression again in the next year
on a fully anchored scale from “very unlikely” (score 1)
to “very likely” (score 5).
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A range of measures are included to examine the factors
shown in Figure 1 in terms of both outcome and media-
tion. Measures include the State-Trait Anxiety Inventory
([STAI - [49]]), International Personality Item Pool Neu-
roticism and Openness to experience subscales [IPIP -
[50,51]]), Five Facet Mindfulness Questionnaire [FFMQ
- [52]]), the Ruminative Response Scale [RRS - [53]]),
the Hill-Bone Medication Taking Scale [54] and locally-
developed measures of mindfulness practice and medi-
cation adherence. Outcome in relation to work and
social functioning is assessed using the Work and Social
Adjustment Scale [WSAS - [55]]) and health-related
q u a l i t yo fl i f eu s i n gt h eA s s e s s m e n to fQ u a l i t yo fL i f e
instrument [AQoL -[56]]).
Economic analysis
Service utilisation by self-report is assessed with instru-
mentation used in the most recent (2007) Australian
National Survey of Mental Health and Wellbeing. This
instrument was used in the first national survey in 1997,
but has been updated to take into account identified
deficiencies in the earlier instrument [57]. It includes
some elements of the service utilisation section of the
WHO CIDI [44]. It also contains questions relating to
levels of perceived need for mental health care and so
provides a consumer appraisal of the relative adequacy
of overall service provision [58-60]. As the instrument
was prepared drawing on a national expert group with
support of the Australian Bureau of Statistics, this likely
represents the best developed instrument for collection
of service utilisation data in Australia.
In order to estimate costs associated with lost produc-
tivity, every 3 months participants in the study are asked
to record the number of days they had been absent from
their usual work or occupation due to illness or disabil-
ity. Also collected is their account of how many of these
days were due to depression or related problems with
their mental health. Employment status and, for those
working, current occupational status are rated using the
Australian and New Zealand Standard Classification of
Occupations [61]. The AQoL will also be used to assess
the cost-utility of MBCT in terms of quality-adjusted
life years (QALYs).
Procedure
Assessments
Experience from pilot work [62] indicated that the pri-
mary reason for exclusion from that study was failure to
meet the selection criteria related to MDD. Referrals to
the project are therefore screened over the phone using
a brief questionnaire based on key questions from the
Depression module of the Lifetime version of the CIDI
2.1. Potentially eligible candidates then are invited to
complete an intake assessment to assess eligibility and
collect baseline data. Following the intake assessment,
eligible participants are randomised in cohorts to treat-
ment condition. For participants in both treatment con-
ditions, PHQ assessments are completed at intake and
then at monthly intervals from the fourth week of the
MBCT program conducted for their cohort. The CIDI
2.1 12 month version, Service Utilization, Hill-Bone
Medication Taking Scale, IPPI, CEQ and Beliefs about
Relapse are completed at 12 months and 24 months fol-
lowing the conclusion of the MBCT program. The CEQ
is also administered at the fourth and eighth week of
the MBCT program and Beliefs about Relapse at 8
weeks. The remaining self-report assessments are admi-
nistered 3 monthly.
Blindness
Considerable efforts are made in this design to maintain
the blindness of raters for the yearly face-to-face assess-
ments including: written and verbal reminders to parti-
cipants; a five-minute videotaped explanation of
blindness by the principal investigator (GM) shown
immediately prior to the 12-month assessment; and a
reminder sign placed prominently in front of the partici-
pant during the course of the interview. Raters are asked
to classify participants into a treatment condition
together with any specific reasons for their guess and an
estimate of their level of certainty. Breaches in rater
blindness are addressed by changing the rater where
possible.
Statistical analysis
Primary outcomes
Intention-to-treat (ITT) analysis will be the primary
analytic framework. Groups will be compared using chi-
square or Fisher’s exact test for proportions and t-test
or Mann-Whitney-test for continuous variables. Time to
relapse/recurrence of depression will be examined using
the Kaplan-Meier survival analysis. The Cox propor-
tional hazards regression analysis will be used to exam-
ine the effect of covariates such as treatment
expectations on time to relapse/recurrence. Per protocol
(PP) analyses will also be undertaken. As in previous
trials, at least four sessions will be considered as the
minimal treatment dose. However, as the MBCT pro-
gram is sequential and participants are strongly encour-
aged to attend all sessions, or at least miss no more
than one [63], we will also examine outcomes for people
who attended the recommended dose of therapy, being
7-8 sessions.
Secondary outcomes and mediation
Secondary outcomes will be examined using repeated-
measures Analysis of Variance (ANOVA) with further
analyses to explore mediation [64,65].
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The incremental cost of MBCT is the cost of treatment
less any savings in health service use. Results of incre-
mental cost-effectiveness analysis will be subject to
extensive probabilistic sensitivity analysis [66] using
@Risk software, which allows the results to be presented
as cost-effectiveness acceptability curves [67]. The cost-
utility of MBCT + DRAM compared to DRAM alone
will be compared using repeated-measures ANOVAs.
As recommended by Hollis and Campbell [68], sensi-
tivity analyses will be undertaken across these analyses
to examine the potential influence of the missing data
using various forms of imputation. Where appropriate,
given the design of the study, multilevel modelling will
be employed [69].
Discussion
This study is a ‘real-world’ examination of MBCT as an
intervention designed to prevent depressive relapse. Set
within a phase 2 translational research framework, its
findings will assist in determining the role that MBCT
can play in routine clinical practice by examining
whether MBCT is an effective intervention for people
with a history of three or more depressive episodes who
are undertaking their usual treatment including antide-
pressants, in a setting outside that of the initial develop-
ing group, and across multiple sites. The sample size,
which is large relative to previously published MBCT
trials, will allow for a secondary outcome and mediation
analysis and so provide further knowledge regarding the
mechanisms by which MBCT may operate to prevent
depressive relapse, both alone and in combination with
pharmacotherapy. The training for therapists delivering
MBCT in the trial is a novel MBCT professional train-
ing program that is relatively brief and does not assume
any background knowledge of meditation on the part of
trainees. This professional training program is poten-
tially an efficient and replicable way of providing com-
prehensive training in the instruction of MBCT to
enable more rapid dissemination in the community.
Positive results from this trial not only would have
implications for ease of translation into the community
and its transportability to new settings but also for
extending our understanding on how much training is
necessary for the effective delivery of MBCT.
The need to balance competing questions of interest is
an important consideration in the design of RCTs. For
example, the recommended comparator for a health
economic analysis is a TAU control [70], while an active
alternative treatment is likely to provide the most infor-
mation for studies investigating mechanisms of action
[e.g., [71]]. As an effectiveness trial, a health economic
analysis is an important aspect of the present study so
favouring the selection of a TAU control in the design.
However, we had the additional need to control for the
potential bias of resentful demoralization and so the
self-monitoring intervention DRAM was introduced as
an addition to TAU. This is likely to mean that episodes
of depression are picked up and treated earlier than
would be the case without such monitoring and possibly
lead to a relative weakening of the between-group
effects for standard symptom measures [72]. Neverthe-
less, we predict that the impetus to access treatment
prompted by DRAM will, if anything, increase between-
group differences in the health economic evaluation and
so this will form a critical focus for examination. In
addition, with respect to relapse outcomes, substantial
reliance will be placed on measures relating to time to
clinical intervention.
Historically, health care systems have been heavily
oriented to the treatment of illness, rather than to its
prevention, resulting in costs that have been described
as spiralling out of control [73]. The argument has been
put forward that where preventative and especially “low
tech” interventions such as mindfulness-based interven-
tions are available, priority should be given to exploring
h o wb e s tt oi m p l e m e n tt h e mf o rg r e a t e s ti m p a c t[ 7 3 ] .
The results of this trial, including an examination of
clinical, functional and health economic outcomes, will
be used to assess the role that this treatment approach
may have in recommendations for treatment of depres-
sion in Australia and elsewhere. We expect that the
findings from this research will consolidate the evi-
dence-base to guide the decision to fund MBCT and to
seek to promote its availability to those who have
experienced at least three episodes of depression.
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